Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells.

Jay FriedmanEllen C MoorePaul ZolkindYvette RobbinsPaul E ClavijoLilian Sun Sarah Greene Megan V MorisadaWojciech K MydlarzNicole SchmittJames W HodgeHans SchreiberCarter Van WaesRavindra UppaluriClint Allen

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Together, these results implicate PD-1 expression by T cells in the mechanism of functional immunodominance among independent T-cell clones within a progressing tumor and support the use of neoadjuvant PD-1 immune checkpoint blockade in patients with surgically resectable carcinomas.

Keyphrases

locally advanced
rectal cancer
lymph node
poor prognosis
squamous cell carcinoma
high grade
liver metastases